Circulating mitochondrial bioenergetic profile reflects the hepatic one and represents a non-invasive biomarker of disease severity in MASLD genetically predisposed individuals
E. Paolini,M. Longo,M. Meroni,P. Podini,A. Quattrini,A.L. Fracanzani,P. Dongiovanni
DOI: https://doi.org/10.1016/j.dld.2024.01.017
IF: 5.165
2024-02-01
Digestive and Liver Disease
Abstract:Introduction Mitochondrial dysfunction is a key player in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) onset and progression. The co-presence of loss-of-function mutations in PNPLA3, TM6SF2 and MBOAT7 genes impacts on mitochondrial morphology and function in in vitro models. Conversely, the restore of MBOAT7 and/or TM6SF2 activity in knock-out HepG2 cells decreased the number of misshapen-dysfunctional mitochondria and improved OXPHOS capacity. Aims To translate our in vitro findings into a clinical perspective and discover novel non-invasive biomarkers, we assessed mitochondrial activity in 41 MASLD patients stratified according to GG-PNPLA3, TT-MBOAT7 and TT-TM6SF2 genotype, of whom frozen liver biopsies and peripheral blood mononuclear cells (PBMCs) were available. Method H2O2, ROS, mitochondrial complexes activities were measured by enzymatic assays, the oxygen consumption rate (OCR) by Seahorse. Results According to our in vitro results, liver biopsies and PBMCs of GG-PNPLA3, TT-MBOAT7 and TT-TM6SF2 carriers, alone and especially combined (number of risk variants, NRV=3), showed higher H2O2 and ROS than MASLD patients with no variants. Consistently, the activity of mitochondrial complexes I, III, citrate and ATP synthase was lower in biopsies and PBMCs of GG-PNPLA3, TT-MBOAT7 and TT-TM6SF2 individuals, showing the sharpest effect in their co-presence (*p<0.05, **p<0.001, ***p<0.0001 vs NRV=0). Finally, biopsies and PBMCs of NRV=3 subjects exhibited OCR depletion yielded by complex I/IV and II/IV activities compared to NRV=0 at Seahorse (***p<0.0001). At multivariate analysis adjusted for age, gender, BMI, diabetes and MASLD severity, NRV=3 was associated with reduced OCR in hepatic biopsies (β=-21.24) and PBMCs (β=-20.08) (p<0.0001). Finally, at nominal logistic analysis, adjusted for NRV=3, OCR predicted MASH-fibrosis with AUC of 0.81 and 0.86 in biopsies and PBMCs, respectively. Conclusion PBMCs mitochondrial activity is impaired in NRV=3 carriers and completely reflects the hepatic one. Therefore, PBMCs bioenergetic profile could represent a potential non-invasive biomarker of disease severity in MASLD genetically predisposed individuals.
gastroenterology & hepatology